ReviewThe European respiratory journal2021
A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.
Review in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Cryobiopsy at the dawn of fibrosis: unlocking early diagnosis and therapeutic windows.Frontiers in medicine · 2026Review
- Global disease burden of interstitial lung disease and pulmonary sarcoidosis, 1990-2021, and forecast analysis over the next decade.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Spatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases.The Journal of pathology · 2025Article
- AI-Based HRCT Quantification in Connective Tissue Disease-Associated Interstitial Lung Disease.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Article
- Correlation between CT-based phenotypes and serum biomarker in interstitial lung diseases.BMC pulmonary medicine · 2024Observational
- Correlation of CT-based radiomics analysis with pathological cellular infiltration in fibrosing interstitial lung diseases.Japanese journal of radiology · 2024Article
- Review
- Solanum nigrum L. in COVID-19 and post-COVID complications: a propitious candidate.Molecular and cellular biochemistry · 2023Review
- Treatable traits: a comprehensive precision medicine approach in interstitial lung disease.The European respiratory journal · 2023Article
- Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease.Inflammopharmacology · 2023Review
- Progressive pulmonary fibrosis: an expert group consensus statement.The European respiratory journal · 2023Review
- Novel diagnostic techniques in interstitial lung disease.Frontiers in medicine · 2023Review
- Clinical status of patients 1 year after hospital discharge following recovery from COVID-19: a prospective cohort study.Annals of intensive care · 2022Article
- Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity.Infection · 2022Article
- Diagnosing interstitial lung disease by multidisciplinary discussion: A review.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrotic interstitial lung diseases (ILDs) frequently have nonspecific and overlapping clinical and radiological features, resulting in ∼10-20% of patients with ILD lacking a clear diagnosis and thus being labelled with unclassifiable ILD. The objective of this review is to describe how patients with unclassifiable ILD should be evaluated, and what impact specific clinical, radiological and histopathological features may have on management decisions, focusing on patients with a predominantly fibrotic phenotype. We highlight recent data that have suggested an increasing role for antifibrotic medications in a variety of fibrotic ILDs, but justify the ongoing importance of making an accurate ILD diagnosis given the benefit of immunomodulatory therapies in many patient populations. We provide a practical approach to support management decisions that can be used by clinicians and tested by clinical researchers, and further identify the need for additional research to support a rational and standardised approach to the management of patients with unclassifiable ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.